Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:184 |
|---|---|
| Enthalten in: |
Cell - 184(2021), 16 vom: 05. Aug., Seite 4220-4236.e13 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.08.2021 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cell.2021.06.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327884509 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327884509 | ||
| 003 | DE-627 | ||
| 005 | 20240320232614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cell.2021.06.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM327884509 | ||
| 035 | |a (NLM)34242578 | ||
| 035 | |a (PII)S0092-8674(21)00755-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2021 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a B.1.617 | |
| 650 | 4 | |a Delta variant | |
| 650 | 4 | |a Receptor-binding-domain | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a escape | |
| 650 | 4 | |a neutralization | |
| 650 | 4 | |a structure | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a variant | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antigen-Antibody Complex |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Ginn, Helen M |e verfasserin |4 aut | |
| 700 | 1 | |a Dejnirattisai, Wanwisa |e verfasserin |4 aut | |
| 700 | 1 | |a Supasa, Piyada |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Beibei |e verfasserin |4 aut | |
| 700 | 1 | |a Tuekprakhon, Aekkachai |e verfasserin |4 aut | |
| 700 | 1 | |a Nutalai, Rungtiwa |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Daming |e verfasserin |4 aut | |
| 700 | 1 | |a Mentzer, Alexander J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yuguang |e verfasserin |4 aut | |
| 700 | 1 | |a Duyvesteyn, Helen M E |e verfasserin |4 aut | |
| 700 | 1 | |a López-Camacho, César |e verfasserin |4 aut | |
| 700 | 1 | |a Slon-Campos, Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, Thomas S |e verfasserin |4 aut | |
| 700 | 1 | |a Skelly, Donal |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Sile Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Ritter, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Mason, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Costa Clemens, Sue Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes Naveca, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, Valdinete |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, Fernanda |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes da Costa, Cristiano |e verfasserin |4 aut | |
| 700 | 1 | |a Resende, Paola Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Pauvolid-Correa, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Siqueira, Marilda M |e verfasserin |4 aut | |
| 700 | 1 | |a Dold, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Temperton, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Julian C |e verfasserin |4 aut | |
| 700 | 1 | |a Crook, Derrick |e verfasserin |4 aut | |
| 700 | 1 | |a Lambe, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Clutterbuck, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Bibi, Sagida |e verfasserin |4 aut | |
| 700 | 1 | |a Flaxman, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Bittaye, Mustapha |e verfasserin |4 aut | |
| 700 | 1 | |a Belij-Rammerstorfer, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Sarah C |e verfasserin |4 aut | |
| 700 | 1 | |a Malik, Tariq |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Miles W |e verfasserin |4 aut | |
| 700 | 1 | |a Klenerman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Eleanor |e verfasserin |4 aut | |
| 700 | 1 | |a Dunachie, Susanna J |e verfasserin |4 aut | |
| 700 | 1 | |a Baillie, Vicky |e verfasserin |4 aut | |
| 700 | 1 | |a Serafin, Natali |e verfasserin |4 aut | |
| 700 | 1 | |a Ditse, Zanele |e verfasserin |4 aut | |
| 700 | 1 | |a Da Silva, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Neil G |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Madhi, Shabir |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Marta C |e verfasserin |4 aut | |
| 700 | 1 | |a Goulder, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Fry, Elizabeth E |e verfasserin |4 aut | |
| 700 | 1 | |a Mongkolsapaya, Juthathip |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Jingshan |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Screaton, Gavin R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell |d 1974 |g 184(2021), 16 vom: 05. Aug., Seite 4220-4236.e13 |w (DE-627)NLM000088935 |x 1097-4172 |7 nnns |
| 773 | 1 | 8 | |g volume:184 |g year:2021 |g number:16 |g day:05 |g month:08 |g pages:4220-4236.e13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cell.2021.06.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 184 |j 2021 |e 16 |b 05 |c 08 |h 4220-4236.e13 | ||